Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q4 2019 · 10-K
Revenue$99.23M$99.23M+42.4% vs Q4 2018 Net Income$4.26M$4.26MN/M vs Q4 2018 EPS Diluted$0.04$0.04N/M vs Q4 2018 Gross Profit$74,448,000+59.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flowderived$6,962,000−58.6% Free Cash Flowderived$3,907,000−70.1% Margins · derivedGross margin75.0%+8.1 pt vs Q4 2018
Operating margin0.2%+12.6 pt vs Q4 2018
Net margin4.3%+26.7 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end